GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoMimetics Inc (NAS:GLYC) » Definitions » Cyclically Adjusted Price-to-FCF

GLYC (GlycoMimetics) Cyclically Adjusted Price-to-FCF : (As of Jul. 09, 2025)


View and export this data going back to 2014. Start your Free Trial

What is GlycoMimetics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


GlycoMimetics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for GlycoMimetics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoMimetics Cyclically Adjusted Price-to-FCF Chart

GlycoMimetics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GlycoMimetics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GlycoMimetics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, GlycoMimetics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoMimetics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoMimetics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GlycoMimetics's Cyclically Adjusted Price-to-FCF falls into.


;
;

GlycoMimetics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

GlycoMimetics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, GlycoMimetics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-7.916/134.9266*134.9266
=-7.916

Current CPI (Mar. 2025) = 134.9266.

GlycoMimetics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -31.426 100.684 -42.114
201509 71.084 100.392 95.537
201512 -36.632 99.792 -49.529
201603 -48.414 100.470 -65.018
201606 -35.848 101.688 -47.566
201609 -33.465 101.861 -44.328
201612 -27.680 101.863 -36.665
201703 -38.830 102.862 -50.934
201706 -23.059 103.349 -30.104
201709 -19.153 104.136 -24.816
201712 -24.642 104.011 -31.966
201803 -29.051 105.290 -37.228
201806 -30.568 106.317 -38.794
201809 -23.459 106.507 -29.719
201812 -23.288 105.998 -29.644
201903 -33.306 107.251 -41.901
201906 -26.551 108.070 -33.149
201909 -31.102 108.329 -38.738
201912 -29.505 108.420 -36.718
202003 -8.046 108.902 -9.969
202006 -33.237 108.767 -41.231
202009 -24.253 109.815 -29.799
202012 -20.258 109.897 -24.872
202103 -27.866 111.754 -33.644
202106 -26.439 114.631 -31.120
202109 -32.849 115.734 -38.296
202112 -24.633 117.630 -28.255
202203 -26.270 121.301 -29.221
202206 -31.053 125.017 -33.515
202209 -16.448 125.227 -17.722
202212 -14.928 125.222 -16.085
202303 -19.220 127.348 -20.364
202306 -10.865 128.729 -11.388
202309 -13.516 129.860 -14.043
202312 -11.826 129.419 -12.329
202403 -16.304 131.776 -16.694
202406 -13.792 132.554 -14.039
202409 -12.394 133.029 -12.571
202412 -5.738 133.157 -5.814
202503 -7.916 134.927 -7.916

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GlycoMimetics  (NAS:GLYC) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


GlycoMimetics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of GlycoMimetics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GlycoMimetics Business Description

Industry
Traded in Other Exchanges
Address
P.O. Box 65, Monrovia, MD, USA, 21770
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
Executives
Invus Public Equities, L.p. 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Edwin Rock officer: Chief Medical Officer 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Brian M. Hahn officer: CFO C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Daniel M Junius director C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451
Bruce S Johnson officer: SVP & Chief Commercial Officer 9708 MEDICAL CENTER DRIVE, BETHESDA MD 20850
Chinmaya Rath officer: SVP and Chief Business Officer 9708 MEDICAL CENTER DR., ROCKVILLE MD 20850
Invus Public Equities Advisors, Llc 10 percent owner C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
Artal Group S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal International S.c.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
S.a. Westend 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Administratiekantoor Westend Stichting 10 percent owner CLAUDE DEBUSSYLAAN, 46, AMSTERDAM P7 1082 MD
Artal International Management S.a. 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Amaury Wittouck 10 percent owner VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L2661
Scott D Sandell 10 percent owner
Harout Semerjian director, officer: Chief Executive Officer 300 THE AMERICAN ROAD, C/O IMMUNOMEDICS, INC., MORRIS PLAINS NJ 07950